Study Condition(s): Non-small Cell Lung Cancer, Gastroesophageal Junction Cancer (GEJ), Transitional Cell Cancer, Stomach Cancer

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium

Study Alias: JVDF

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02443324 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug, known as ramucirumab, plus pembrolizumab in participants with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or transitional cell carcinoma of the urothelium.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

Participation in this trial could last up to 6 months, depending on how you and your tumor respond
  • Participant must have confirmed gastric or GEJ adenocarcinoma with documented disease progression after 1-2 prior lines of systemic therapy or

  • Participant must have confirmed nonsquamous or squamous NSCLC with documented disease progression after 1-3 prior lines of systemic therapy or

  • Participant must have confirmed transitional cell carcinoma of the urothelium (bladder, urethra, or renal pelvis) with documented disease progression after 1-3 prior lines of systemic therapy

  • Participant must have tumor tissue available for biomarker analysis from a newly obtained core or excisional biopsy or willing to undergo a tumor biopsy

  • Participant must have adequate organ function

  • Participant must not have known brain metastases

  • Participant must not have active autoimmune disease, known HIV infection, or known active hepatitis B or hepatitis C infection

  • Participant must not have an elective or planned major surgery during the course of the trial or has undergone major surgery within 28 days prior to enrollment

Where to Participate

22 locations are currently available of 22 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.